

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/751,354

Confirmation No.: 2231

Applicant(s) : Dey et al.

Filed : 1/5/04

TC/A.U. : 1624

Examiner : James O. Wilson

For : Active Esters of N-Substituted Piperazine Acetic Acids, Including Isotopically enriched Versions thereof

Customer No. : 23544

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited via EFS web addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Date of Deposit: 5-4-07

Signature: *Patricia E. Tocci*

Name of Depositing Party: Patricia E. Tocci

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information listed on the attached Information Disclosure Statement of which they are aware, which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement:

- (a) ☐ accompanies a new patent application submitted herewith.
- (b) ☐ is filed within three months after the filing date of the application or within three months after the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491.
- (c) ☐ as far as is known to the undersigned, is filed before the mailing date of a first Office action on the merits.
- (d) ☐ as far as is known to the undersigned, is filed before the mailing date of a first

- Office action after the filing of a request for continued examination under § 1.114.
- (e) ☒ is filed after the first Office Action and more than three months after the application's filing date or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final action under § 1.113, a notice of allowance under § 1.311, whichever occurs first, and is accompanied by either the fee (\$180) set forth in 37 CFR § 1.17(p) or a certification as specified in 37 CFR § 1.97(e), as checked below. Should any fee be due, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 01-2213 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement. Any deficiency or overpayment should be charged or credited to this deposit account. **A duplicate of this sheet is enclosed.**
- (f) ☐ is filed after the mailing date of either a final rejection or a notice of allowance, but on or before the payment of the issue fee, and is accompanied by the fee (\$180) set forth in 37 CFR § 1.17(i)(1) and a certification as specified in 37 CFR § 1.97(e), as checked below. **This document is to be considered as a petition requesting consideration of the information disclosure statement.** The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 01-2213 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement. Any deficiency or overpayment should be charged or credited to this deposit account. **A duplicate of this sheet is enclosed.**

[If either of boxes (e) or (f) is checked above, the following "certification" under 37 CFR § 1.97(e) may need to be completed.] The undersigned certifies that:

- ☐ Each item of information contained in the information disclosure statement was first cited in a communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☒ No item of information contained in this information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this information disclosure statement.

A copy of the items on the Information Disclosure Statement that are not United States Publications:

☒ are supplied herewith.

☐ are not supplied because they were previously cited by or submitted to the Office in application Serial No. _____, filed _____ and relied upon in this application for an earlier filing date under 35 USC § 120.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

Date: May 4, 2007

/Brian D. Gildea/

Brian D. Gildea
Attorney for Applicants
Reg. No. 39,995
Telephone: 508-383-7632
Customer No.: 23544

Applied Biosystems
500 Old Connecticut Path
Framingham, MA 01701

U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE				Atty Docket No. BP0306-US		Application No. 10/751,354	
REFERENCES CITED BY APPLICANTS				Applicant			
(Use several sheets if necessary)				Dey, Subhakar et al.			
				Filing Date		Group	
				01/05/2004		1624	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
							TRANSLATION
		DOCUMENT Number	DATE	COUNTRY	CLASS	SUBCLASS	YES NO
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
GS		Malawska et al., "Structure-Activity Relationship Studies of New N-Substituted Amides of α -Piperazine- γ -Hydroxybutyric Acid as Active Anticonvulsants", Arch Pharm Pharm Med Chem, vol. 330, 1997, pgs 91-99					
GT		Rautio, J. et al. "Synthesis and in Vitro Evaluation of Novel Morpholinyl- and Methylpiperazinylacloxyalkyl Prodrugs of 2-(6-Methoxy-2-naphthyl) propionic Acid (naproxen) for Topical Drug Delivery", J Med Chem, vol. 43, no. 8, 20 April 2000, pgs 1489-1494					
Examiner				Date Considered			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.							